XERS Stock Overview
A biopharmaceutical company, engages in developing and commercializing therapies in Illinois. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.47 |
| 52 Week High | US$3.87 |
| 52 Week Low | US$1.69 |
| Beta | 1.24 |
| 1 Month Change | 9.12% |
| 3 Month Change | 20.91% |
| 1 Year Change | 47.03% |
| 3 Year Change | 42.80% |
| 5 Year Change | n/a |
| Change since IPO | 47.03% |
Recent News & Updates
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Oct 25Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks
Sep 07
Recent updates
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Oct 25Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks
Sep 07Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company
Jun 04Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Mar 30Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results
Mar 09Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up
Mar 06Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth
Jan 05Xeris Pharmaceuticals Q2 2022 Earnings Preview
Aug 09Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal
Aug 01Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
May 21Xeris Continues To Execute And Build Long-Term Value Potential
Feb 22Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition
Dec 20Shareholder Returns
| XERS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.8% | 0.6% | -0.4% |
| 1Y | 47.0% | 10.0% | 24.8% |
Return vs Industry: XERS exceeded the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: XERS exceeded the US Market which returned 24.8% over the past year.
Price Volatility
| XERS volatility | |
|---|---|
| XERS Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XERS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XERS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 377 | John Shannon | www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
| XERS fundamental statistics | |
|---|---|
| Market cap | US$517.31m |
| Earnings (TTM) | -US$63.11m |
| Revenue (TTM) | US$187.36m |
2.8x
P/S Ratio-8.2x
P/E RatioIs XERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XERS income statement (TTM) | |
|---|---|
| Revenue | US$187.36m |
| Cost of Revenue | US$34.92m |
| Gross Profit | US$152.44m |
| Other Expenses | US$215.55m |
| Earnings | -US$63.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 81.36% |
| Net Profit Margin | -33.69% |
| Debt/Equity Ratio | -816.6% |
How did XERS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:35 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xeris Biopharma Holdings, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Oren Livnat | H.C. Wainwright & Co. |